Table 1.
Main characteristics of the analysed cohort for microbe-host interaction.
| Characteristics | HC | UC/IBDU | CD | Total IBD cohort |
|---|---|---|---|---|
| [n = 36] | [n = 52] | [n = 46] | [n = 98] | |
| Median age, y [range] | 57 [41–71] | 34 [19–64] | 29 [17–67] | 33 [17–67] |
| Sex, n female [%] | 14 [38.9] | 31 [59.6] | 23 [50.0] | 54 [55.1] |
| Median age at diagnosis of IBD, y [range] | - | 25 [11–56] | 21 [7–57] | 22.5 [7–57] |
| Median duration of IBD, y [range] | - | 8 [1–44] | 8 [0–30] | 8 [0–44] |
| Montreal classification, n | ||||
| CD location, L1/L2/L3 | - | - | 5/15/26 | - |
| CD behaviuor, B1/B2/B3 | - | - | 27/8/11 | - |
| UC extent, E1/E2/E3 | - | 10/16/26 | - | - |
| Primary sclerosing cholangitis, n [%] | - | 3 [5.8] | 1 [2.2] | 4 [4.1] |
| Prior history of Ileocaecal resection, n [%] | - | - | 4 [8.7] | - |
| Medication at colonoscopy | ||||
| 5-aminosalicylates, n [%] | - | 41 [78.8] | 8 [17.4] | 49 [50.0] |
| Immunomodulators, n [%] | - | 3 [5.8] | 10 [21.7] | 13 [13.3] |
| Biologic therapy, n [%] | - | 5 [9.6] | 9 [19.6] | 14 [14.3] |
| Corticosteroids, n [%] | - | 3 [5.8] | 0 | 3 [3.1] |
| Inflamed mucosaa | ||||
| Terminal ileum, n/total samples [%] | 0/23 | 0/23 | 10/21 [46.7] | 10/44 [22.7] |
| Ascending colon, n/total samples [%] | 0/2 | 4/15 [26.7] | 4/11 [36.3] | 8/26 [31.0] |
| Sigmoid colon, n/total samples [%] | 0/30 | 21/41 [51.2] | 19/40 [50.6] | 40/81 [49.3] |
HC, healthy controls; UC, ulcerative colitis; IBDU, inflammatory bowel disease unclassified; CD, Crohn´s disease; y, years.
aPercentages are based on the total number of samples per site as denominator.